Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $28.1 million.

  • Tg Therapeutics' Other Operating Expenses rose 20074.94% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.0 million, marking a year-over-year increase of 15200.71%. This contributed to the annual value of $38.5 million for FY2024, which is 17235.16% up from last year.
  • Per Tg Therapeutics' latest filing, its Other Operating Expenses stood at $28.1 million for Q3 2025, which was up 20074.94% from $18.9 million recorded in Q2 2025.
  • Tg Therapeutics' Other Operating Expenses' 5-year high stood at $28.1 million during Q3 2025, with a 5-year trough of $2000.0 in Q3 2022.
  • Its 5-year average for Other Operating Expenses is $6.1 million, with a median of $1.9 million in 2023.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first plummeted by 9931.51% in 2022, then surged by 26170000.0% in 2023.
  • Tg Therapeutics' Other Operating Expenses (Quarter) stood at $210000.0 in 2021, then crashed by 98.57% to $3000.0 in 2022, then surged by 261700.0% to $7.9 million in 2023, then soared by 96.07% to $15.4 million in 2024, then soared by 82.43% to $28.1 million in 2025.
  • Its Other Operating Expenses was $28.1 million in Q3 2025, compared to $18.9 million in Q2 2025 and $15.5 million in Q1 2025.